Cellectar Biosciences, Inc.
CLRBW
CLRBW was delisted on the 20th of August, 2019.
4 hedge funds and large institutions have $4K invested in Cellectar Biosciences, Inc. in 2018 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
43% less capital invested
Capital invested by funds: $7K → $4K (-$3K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $3K | – | – | – |
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1K | – | +5 | +0% |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$9 | -100 | -21% |
|
CLRBW Hedge Fund Activity: Q4 2018 in Review
4 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. (CLRBW) for Q4 2018, worth a combined $4K — down 43% from $7K a quarter earlier.
Fund positioning in CLRBW was balanced in Q4 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $9.
- 4 institutional investors held Cellectar Biosciences, Inc. (CLRBW) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $4K of Cellectar Biosciences, Inc. stock for Q4 2018, down 43% quarter-over-quarter.
- 0 funds opened new Cellectar Biosciences, Inc. positions in Q4 2018 and 0 closed out.
- The largest Cellectar Biosciences, Inc. seller in Q4 2018 was UBS Group, an estimated $9 sold.
Based on aggregated 13F filings for Q4 2018.